[Purification of an endogenous inhibitor of sodium-potassium-ATPase].
From human plasma of healthy subject, an inhibitor of Na+, K+-ATPase was prepared, using a gel filtration followed by anion exchange chromatography and by HPLC on reverse phase. This low molecular weight (less than 1,500 dalton) inhibitor is a substance which possesses anionic charges, and is absorbed on reverse phase. It inhibits Na+, K+-ATPase activity and the 3H-ouabain binding on human red blood cells.
D000818:Animals; D004285:Dogs; D004791:Enzyme Inhibitors / Q000302:isolation & purification* / Q000494:pharmacology; D004910:Erythrocyte Membrane / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000201:enzymology; D010042:Ouabain / Q000378:metabolism; D011485:Protein Binding; D011955:Receptors, Drug / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D011955:Receptors, Drug; C028996:cardiac glycoside receptors; D010042:Ouabain; D000254:Sodium-Potassium-Exchanging ATPase
Purification d'un inhibiteur endogène de la sodium-potassium-ATPase.